Goldman Sachs’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-376,738
| Closed | -$18M | – | 6824 |
|
|
2025
Q3 | $18M | Buy |
376,738
+197,017
| +110% | +$5.46M | ﹤0.01% | 2361 |
|
|
2025
Q2 | $2.87M | Buy |
179,721
+96,802
| +117% | +$1.57M | ﹤0.01% | 3895 |
|
|
2025
Q1 | $1.26M | Sell |
82,919
-22,210
| -21% | -$356K | ﹤0.01% | 4512 |
|
|
2024
Q4 | $2.13M | Buy |
105,129
+33,130
| +46% | +$834K | ﹤0.01% | 4221 |
|
|
2024
Q3 | $1.85M | Sell |
71,999
-35,409
| -33% | -$591K | ﹤0.01% | 4221 |
|
|
2024
Q2 | $1.38M | Sell |
107,408
-90,511
| -46% | -$1.46M | ﹤0.01% | 4223 |
|
|
2024
Q1 | $4.53M | Buy |
197,919
+188,916
| +2,098% | +$6.66M | ﹤0.01% | 3180 |
|
|
2023
Q4 | $236K | Buy |
9,003
+8,128
| +929% | +$163K | ﹤0.01% | 5093 |
|
|
2023
Q3 | $246K | Sell |
875
-1,045
| -54% | -$30.6K | ﹤0.01% | 4971 |
|
|
2023
Q2 | $58.4K | Sell |
1,920
-176
| -8% | -$4.49K | ﹤0.01% | 5447 |
|
|
2023
Q1 | $39.4K | Sell |
2,096
-1,892
| -47% | -$31.2K | ﹤0.01% | 5586 |
|
|
2022
Q4 | $40.7K | Buy |
3,988
+757
| +23% | +$12.2K | ﹤0.01% | 5620 |
|
|
2022
Q3 | $85K | Buy |
3,231
+788
| +32% | +$28.7K | ﹤0.01% | 5723 |
|
|
2022
Q2 | $110K | Sell |
2,443
-39
| -2% | -$3.08K | ﹤0.01% | 5827 |
|
|
2022
Q1 | $244K | Buy |
2,482
+173
| +7% | +$16.2K | ﹤0.01% | 5772 |
|
|
2021
Q4 | $353K | Buy |
+2,309
| New | +$342K | ﹤0.01% | 5586 |
|
Goldman Sachs's TRML Position: Q4 2025 in Review
Goldman Sachs sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 376,738 shares — an estimated $18M sold.
Goldman Sachs first reported a position in TRML in Q4 2021 and held it in 16 quarters. The position peaked at $18M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Goldman Sachs reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Goldman Sachs sold 376,738 Tourmaline Bio shares in Q4 2025, an estimated $18M.
- Goldman Sachs first reported a position in Tourmaline Bio in Q4 2021 and held it in 16 quarters.
- Goldman Sachs's Tourmaline Bio position peaked at $18M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.